In this episode, host Shikha Jain, MD, speaks with Jonathan D. Licht, MD, about becoming and training qualified leaders in the field, challenges facing health care leaders and more. • Welcome to another exciting episode of Oncology Overdrive :58 • About Licht 1:16 • The interview 3:17 • Can you tell us about your journey into hematology-oncology and how you ended up where you are today? 3:58 • How have you found the time and ability to balance and succeed in the research, clinical, translational and leadership parts of your work? 9:05 • What do you suggest to people who are currently trying to get into leadership positions in their early-to-mid career? 12:52 • Do you agree with the sentiment that there are some leaders in the field who are put into positions prematurely or are ineffective? As a leader, how do you address the need for further training of future leaders? 18:39 • What are some of the leadership challenges you have seen in the last several years, and how have you managed to navigate them? 23:20 • How did you use your leadership skills to navigate the first few years of the pandemic, and how are you continuing to navigate delivery of care post-pandemic? 29:23 • Tell me about the process of achieving NCI designation and what it means for your institution. 36:25 • How have you had to navigate state health care legislation and policies challenging reproductive health care? 42:16 • If someone could only listen to the last minute of this episode, what would you want them to take away? 46:13 • How to contact Licht 46:56 • Thanks for listening 48:16 Jonathan D. Licht, MD, is the director of the University of Florida Health Cancer Center.
We’d love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow Healio on X, formerly known as Twitter, and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X, formerly known as Twitter: @ShikhaJainMD. Licht can be reached on X, formerly known as Twitter, @jdlicht or via email [email protected]. Disclosures: Jain reports no relevant financial disclosures. Licht reports consultancy for AstraZeneca and research funding for Epizyme.